Article
Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction.
Gastroenterology - 1 Oct 2010
Thompson Alexander J, Fellay Jacques, Patel Keyur, Tillmann Hans L, Naggie Susanna, Ge Dongliang, Urban Thomas J, Shianna Kevin V, Muir Andrew J, Fried Michael W, Afdhal Nezam H, Goldstein David B, McHutchison John G
Abstract excerpt
BACKGROUND & AIMS: In a genome-wide association study of patients being treated for chronic hepatitis C, 2 functional variants in ITPA that cause inosine triphosphatase (ITPase) deficiency were shown to protect against ribavirin (RBV)-induced hemolytic anemia during early stages of treatment. We aimed to replicate this finding in an independent cohort from the Study of Viral Resistance to Antiviral Therapy of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.